13:44:30 EST Sat 27 Feb 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for C:RVV from 2020-02-27 to 2021-02-26 - 85 items News ReleasesIn The NewsOther CAUS
DateSymCompanyPriceTypeHeadline
2021-02-26 10:42C:RVVRevive Therapeutics Ltd0.46News ReleaseRevive Therapeutics to expand bucillamine COVID study
2021-02-26 08:33C:RVVRevive Therapeutics Ltd.0.46News ReleaseRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
2021-02-17 11:09C:RVVRevive Therapeutics Ltd0.62News ReleaseRevive to acquire psilocybin IP for $10-million
2021-02-12 10:14C:RVVRevive Therapeutics Ltd0.69News ReleaseRevive closes $23-million prospectus offering
2021-02-11 09:41C:RVVRevive Therapeutics Ltd0.60News ReleaseRevive talks cannabinoid pharmaceuticals program
2021-02-09 17:06C:RVVRevive Therapeutics Ltd0.54News ReleaseRevive receives receipt for final prospectus
2021-02-09 15:52C:RVVRevive Therapeutics Ltd0.53SEDAR Final Short Form ProspectusSEDAR Final Short Form Prospectus
2021-02-08 17:46C:RVVRevive Therapeutics Ltd0.53News ReleaseRevive Therapeutics files report on Psilocin agreement
2021-01-26 19:06C:RVVRevive Therapeutics Ltd0.64SEDAR Annual Information FormSEDAR Annual Information Form
2021-01-26 12:19C:RVVRevive Therapeutics Ltd0.64SEDAR Preliminary Short Form ProspectusSEDAR Preliminary Short Form Prospectus
2021-01-26 08:51C:RVVRevive Therapeutics Ltd0.61SEDAR MD & ASEDAR MD & A
2021-01-26 08:45C:RVVRevive Therapeutics Ltd0.61SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2021-01-22 11:13C:RVVRevive Therapeutics Ltd0.55News ReleaseRevive Therapeutics joins Horizons' psychedelic ETF
2021-01-21 11:27C:RVVRevive Therapeutics Ltd0.55News ReleaseRevive Therapeutics increases offering to $20-million
2021-01-21 10:00C:RVVRevive Therapeutics Ltd0.60Resume TradingRevive Therapeutics to resume at 7:15 a.m. PT
2021-01-21 07:52C:RVVRevive Therapeutics Ltd0.60Halt TradingRevive Therapeutics halted at open
2021-01-20 17:48C:RVVRevive Therapeutics Ltd0.60News ReleaseRevive Therapeutics arranges $10-million bought deal
2021-01-14 08:29C:RVVRevive Therapeutics Ltd0.62News ReleaseRevive to work on biosynthetic version of psilocybin
2020-12-31 08:15C:RVVRevive Therapeutics Ltd0.62News ReleaseRevive appoints Fahy as scientific, clinical adviser
2020-12-23 10:05C:RVVRevive Therapeutics Ltd0.69News ReleaseRevive expects to meet enrolment goals in phase 3 trial
2020-12-21 09:45C:RVVRevive Therapeutics Ltd0.68News ReleaseRevive to acquire Newscope unit's psilocybin assets
2020-12-02 13:28C:RVVRevive Therapeutics Ltd0.27News ReleaseRevive appoints Moody as medical, clinical adviser
2020-11-27 19:06C:RVVRevive Therapeutics Ltd0.29SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2020-11-27 19:06C:RVVRevive Therapeutics Ltd0.29SEDAR MD & ASEDAR MD & A
2020-11-24 12:16C:RVVRevive Therapeutics Ltd0.25News ReleaseNewscope's PharmaTher talks psychedelic pharma programs
2020-11-18 08:27C:RVVRevive Therapeutics Ltd0.215News ReleaseRevive, PharmaTher to work on psilocybin research
2020-11-11 10:04C:RVVRevive Therapeutics Ltd0.21News ReleaseRevive completes developing film strip prototype
2020-10-28 21:10C:RVVRevive Therapeutics Ltd0.18SEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2020-10-28 21:10C:RVVRevive Therapeutics Ltd0.18SEDAR MD & ASEDAR MD & A
2020-10-26 10:07C:RVVRevive Therapeutics Ltd0.21News ReleaseRevive Therapeutics commits to 10 U.S. clinical sites
2020-10-20 07:39C:RVVRevive Therapeutics Ltd0.245News ReleaseRevive contracts HAVN to source psychedelic compounds
2020-09-29 09:36C:RVVRevive Therapeutics Ltd0.29News ReleaseRevive selects phase 3 bucillamine COVID trial sites
2020-09-21 10:13C:RVVRevive Therapeutics Ltd0.26News ReleaseRevive talks psychedelic therapeutic programs
2020-09-16 08:29C:RVVRevive Therapeutics Ltd0.245News ReleaseRevive garners IRB nod for bucillamine protocol
2020-09-02 10:15C:RVVRevive Therapeutics Ltd0.275News ReleaseRevive Therapeutics signs clinical trial deal with UWS
2020-08-31 09:07C:RVVRevive Therapeutics Ltd0.28News ReleaseRevive receives IRB OK for phase 3 Bucillamine protocol
2020-08-31 08:51C:RVVRevive Therapeutics Ltd0.28Resume TradingRevive Therapeutics to resume at 6:30 a.m. PT
2020-08-31 08:31C:RVVRevive Therapeutics Ltd0.28Halt TradingRevive Therapeutics halted at 5:29 a.m. PT
2020-08-26 10:00C:RVVRevive Therapeutics Ltd0.265Resume TradingRevive Therapeutics to resume at 7:30 a.m. PT
2020-08-26 09:30C:RVVRevive Therapeutics Ltd0.265News ReleaseRevive submits clinical trial protocol for IRB approval
2020-08-26 08:44C:RVVRevive Therapeutics Ltd0.265Halt TradingRevive Therapeutics halted at 5:39 a.m. PT
2020-08-19 12:31C:RVVRevive Therapeutics Ltd0.28News ReleaseRevive to expand phase 3 trials into APAC, Canada
2020-08-19 12:29C:RVVRevive Therapeutics Ltd0.28Resume TradingRevive Therapeutics to resume at 10 a.m. PT
2020-08-19 12:03C:RVVRevive Therapeutics Ltd0.28Halt TradingRevive Therapeutics halted at 8:59 a.m. PT
2020-08-14 10:17C:RVVRevive Therapeutics Ltd0.30News ReleaseRevive, Attwill sign MOU for packaging in drug trial
2020-08-11 11:17C:RVVRevive Therapeutics Ltd0.36News ReleaseRevive receives 1st set of film strips for psychedelics
2020-08-05 11:39C:RVVRevive Therapeutics Ltd0.405News ReleaseRevive to begin phase 3 Bucillamine trial in Sept.
2020-07-31 09:29C:RVVRevive Therapeutics Ltd0.235Resume TradingRevive Therapeutics to resume at 7 a.m. PT
2020-07-31 09:07C:RVVRevive Therapeutics Ltd0.235News ReleaseRevive gets green light for phase 3 Bucillamine trial
2020-07-31 08:29C:RVVRevive Therapeutics Ltd0.235Halt TradingRevive Therapeutics halted at 5:27 a.m. PT
2020-07-02 09:32C:RVVRevive Therapeutics Ltd0.305Resume TradingRevive Therapeutics resumes at 6:30 a.m. PT
2020-06-30 15:55C:RVVRevive Therapeutics Ltd0.29News ReleaseRevive submits IND application to FDA
2020-06-30 12:59C:RVVRevive Therapeutics Ltd0.255Halt TradingRevive Therapeutics halted at 9:56 a.m. PT
2020-06-12 08:32C:RVVRevive Therapeutics Ltd0.225News ReleaseRevive expands psilocybin research deal with university
2020-06-09 14:16C:RVVRevive Therapeutics Ltd0.31News ReleaseRevive has pre-CTA meeting with Health Canada
2020-06-03 11:32C:RVVRevive Therapeutics Ltd0.295Resume TradingRevive Therapeutics to resume at 8:45 a.m. PT
2020-06-03 11:18C:RVVRevive Therapeutics Ltd0.295News ReleaseRevive files CTA with Health Canada for bucillamine
2020-06-03 10:49C:RVVRevive Therapeutics Ltd0.295Halt TradingRevive Therapeutics halted at 7:47 a.m. PT
2020-05-29 19:06C:RVVRevive Therapeutics Ltd0.29SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2020-05-29 19:06C:RVVRevive Therapeutics Ltd0.29SEDAR MD & ASEDAR MD & A
2020-05-13 12:46C:RVVRevive Therapeutics Ltd0.145News ReleaseRevive to submit IND package to FDA for bucillamine
2020-04-29 10:45C:RVVRevive Therapeutics Ltd0.14News ReleaseRevive Therapeutics talks psilocybin program details
2020-04-23 09:33C:RVVRevive Therapeutics Ltd0.185Resume TradingRevive Therapeutics to resume at 7 a.m. PT
2020-04-23 08:45C:RVVRevive Therapeutics Ltd0.185News ReleaseRevive's Bucillamine gets FDA OK to go to phase 3 trial
2020-04-23 08:22C:RVVRevive Therapeutics Ltd0.185Halt TradingRevive Therapeutics halted at 5:17 a.m. PT
2020-04-21 11:49C:RVVRevive Therapeutics Ltd0.165News ReleaseRevive enters psilocybin pharmaceuticals partnership
2020-04-17 08:30C:RVVRevive Therapeutics Ltd0.125News ReleaseRevive hires Complete Phyto for psilocybin R&D
2020-04-15 10:55C:RVVRevive Therapeutics LtdNews ReleaseRevive closes $820,000 2nd tranche of private placement
2020-04-08 10:29C:RVVRevive Therapeutics Ltd0.145News ReleaseRevive hires Novotech as clinical research organization
2020-04-03 10:31C:RVVRevive Therapeutics Ltd0.115Resume TradingRevive Therapeutics to resume at 7:30 a.m. PT
2020-04-03 10:22C:RVVRevive Therapeutics Ltd0.105News ReleaseRevive files pre-IND meeting request with FDA
2020-04-03 09:28C:RVVRevive Therapeutics Ltd0.115Halt TradingRevive Therapeutics halted at 6:26 a.m. PT
2020-04-03 07:18C:RVVRevive Therapeutics Ltd0.105News ReleaseRevive warns holders of buy recommendations
2020-03-30 07:22C:RVVRevive Therapeutics Ltd0.11News ReleaseRevive works on Bucillamine clinical development
2020-03-25 17:54C:RVVRevive Therapeutics Ltd0.08News ReleaseRevive hires Pharm-Olam to study COVID-19 treatment
2020-03-24 10:31C:RVVRevive Therapeutics Ltd0.08Resume TradingRevive Therapeutics to resume at 7:45 a.m. PT
2020-03-24 10:20C:RVVRevive Therapeutics Ltd0.085News ReleaseRevive appoints Boulware as scientific adviser
2020-03-24 09:24C:RVVRevive Therapeutics Ltd0.08Halt TradingRevive Therapeutics halted at 6:21 a.m. PT
2020-03-20 07:11C:RVVRevive Therapeutics Ltd0.06News ReleaseRevive looks into using Bucillamine to treat Covid-19
2020-03-18 13:28C:RVVRevive Therapeutics Ltd0.045News ReleaseRevive closes $1.67-million private placement
2020-03-05 15:09C:RVVRevive Therapeutics Ltd0.10Resume TradingRevive Therapeutics to resume trading at 12:30 p.m. PT
2020-03-05 14:42C:RVVRevive Therapeutics Ltd0.10News ReleaseRevive completes Psilocin Pharma acquisition
2020-03-05 09:45C:RVVRevive Therapeutics Ltd0.10Halt TradingRevive Therapeutics halted at 6:36 a.m. PT
2020-02-28 18:15C:RVVRevive Therapeutics Ltd0.055SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2020-02-28 18:15C:RVVRevive Therapeutics Ltd0.055SEDAR MD & ASEDAR MD & A